(2-{2-[2-(2-bromoethoxy)ethoxy]ethoxy}ethoxy)-tert-butyl-dimethylsilane | 878052-24-5

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: (2-{2-[2-(2-bromoethoxy)ethoxy]ethoxy}ethoxy)-tert-butyl-dimethylsilane
• 英文别名: (2-{2-[2-(2-Bromo-ethoxy)-ethoxy]-ethoxy}-ethoxy)-tert-butyl-dimethyl-silane；2-[2-[2-(2-bromoethoxy)ethoxy]ethoxy]ethoxy-tert-butyl-dimethylsilane
• CAS: 878052-24-5
• 化学式: C₁₄H₃₁BrO₄Si
• 分子量: 371.387
• InChiKey: FHLVUEBYSRRMNA-UHFFFAOYSA-N

物化性质

• 沸点：
  359.8±27.0 °C(Predicted)
• 密度：
  1.111±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.45
• 重原子数：
  20
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2-{2-[2-(2-bromoethoxy)ethoxy]ethoxy}ethoxy)-tert-butyl-dimethylsilane 在 4-二甲氨基吡啶 、 四丁基氟化铵 、 caesium carbonate 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 4-[2-[2-[2-[2-[(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(3-carboxy-3-methylbutanoyl)oxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carbonyl]oxyethoxy]ethoxy]ethoxy]ethoxy]-2,2-dimethyl-4-oxobutanoic acid
  参考文献：
  名称：

  Anti-AIDS Agents 90. Novel C-28 Modified Bevirimat Analogues as Potent HIV Maturation Inhibitors

  摘要：

  In a continuing study of bevirimat (2), the anti-HIV-maturation clinical trials agent, 28 new betulinic acid (BA, 1) derivatives were designed and synthesized. Among these compounds, 17, with a C-28 MEM ester moiety, and 22, with a C-28 ethyl hexanoate, increased the anti-HIV replication activity compared with 2 by 2-fold while compounds 40, 41, 48, and 49, with C-28 piperazine or piperidine amide substitutions, increased the activity by 3- to 15-fold. The best new compound, 41, exhibited an anti-HIV IC50 of 0.0059 mu M compared with 0.087 mu M antimaturation effects, as confirmed by TZM-bl assay, in blocking the HIV replication. The results suggest that proper C-28 substitutions can further enhance the antimaturation activity of 2 without any antientry effects. Thus, 41 may serve as a promising new lead for development of anti-AIDS clinical trial candidates.

  DOI：

  10.1021/jm301040s
• 作为产物：
  描述：

  13,13,14,14-四甲基-3,6,9,12-四氧杂-13-硅-1-十五醇 在 吡啶 、 四溴化碳 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 以79.6%的产率得到(2-{2-[2-(2-bromoethoxy)ethoxy]ethoxy}ethoxy)-tert-butyl-dimethylsilane
  参考文献：
  名称：

  WO2006/66104

  摘要：

  公开号：

文献信息

• Design, Synthesis, and Biological Investigation of Epothilone B Analogues Featuring Lactone, Lactam, and Carbocyclic Macrocycles, Epoxide, Aziridine, and 1,1-Difluorocyclopropane and Other Fluorine Residues
  作者：K. C. Nicolaou、Yogesh G. Shelke、Balu D. Dherange、Aaron Kempema、Baiwei Lin、Christine Gu、Joseph Sandoval、Mikhail Hammond、Monette Aujay、Julia Gavrilyuk

  DOI：10.1021/acs.joc.0c00123

  日期：2020.3.6

  with an NCO-alkyl residue (imide or carbamate). Biological evaluation of these analogues revealed a number of exceptionally potent epothilone B analogues, demonstrating the potency enhancing effects of the fluorine residues and the aziridinyl moiety within the structure of the epothilone molecule and providing new and useful structure-activity relationships within this class of compounds.

  尽管在埃坡霉素领域进行了先前的研究，但该化合物家族中只有一个成员ixabepilone批准用于临床。有机合成和药物化学的最新进展使埃博霉素铅类似物进一步优化，旨在提高其效力和其他药理特性，这是对发现和开发新的抗癌药物（包括抗体-药物缀合物作为潜在的靶向癌症治疗方法）的追求的一部分。本文中，我们报告了一系列新型Epothilone B类似物的设计，合成和生物学评估，这些类似物配备了新颖的结构基序，包括含氟残基，12,13-二氟环丙基部分，单和二甲基化大内酯和1-酮大环系统，以及两个N-取代的ixabepilone类似物，其中的12 取代13-环氧化物和大内酰胺NH部分，前者具有取代的氮丙啶部分，而后者具有NCO-烷基残基（酰亚胺或氨基甲酸酯）。这些类似物的生物学评估揭示了许多异常有效的埃坡霉素B类似物，证明了埃坡霉素分子结构内氟残基和氮丙啶基部分的效力增强作用，并在此类化合物中提供了新的有用的构效关系。
• Stilbene derivatives and their use for binding and imaging amyoid plaques
  申请人：Kung F. Hank

  公开号：US20060269473A1

  公开（公告）日：2006-11-30

  This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.

  本发明涉及成像淀粉样沉积物的方法以及标记化合物，以及制备用于成像淀粉样沉积物的标记化合物的方法。本发明还涉及化合物以及制备化合物的方法，用于抑制淀粉样蛋白聚集形成淀粉样沉积物，并将治疗剂输送到淀粉样沉积物。
• Stilbene derivatives and their use for binding and imaging amyloid plaques
  申请人：Kung F. Hank

  公开号：US20060269474A1

  公开（公告）日：2006-11-30

  This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.

  本发明涉及一种成像淀粉样沉积物的方法，以及标记化合物和制备标记化合物的方法，以用于成像淀粉样沉积物。此外，本发明还涉及化合物和制备化合物的方法，以抑制淀粉样蛋白聚集形成淀粉样沉积物，并将治疗剂递送到淀粉样沉积物的方法。
• STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES
  申请人：Kung Hank F.

  公开号：US20100266500A1

  公开（公告）日：2010-10-21

  This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.

  本发明涉及一种成像淀粉样沉积物的方法，以及标记化合物和制备标记化合物的方法，以便成像淀粉样沉积物。本发明还涉及化合物，以及制备化合物的方法，用于抑制淀粉样蛋白聚集形成淀粉样沉积物，并且涉及将治疗剂输送到淀粉样沉积物的方法。
• Anti-AIDS Agents 90. Novel C-28 Modified Bevirimat Analogues as Potent HIV Maturation Inhibitors
  作者：Keduo Qian、Ibrahim D. Bori、Chin-Ho Chen、Li Huang、Kuo-Hsiung Lee

  DOI：10.1021/jm301040s

  日期：2012.9.27

  In a continuing study of bevirimat (2), the anti-HIV-maturation clinical trials agent, 28 new betulinic acid (BA, 1) derivatives were designed and synthesized. Among these compounds, 17, with a C-28 MEM ester moiety, and 22, with a C-28 ethyl hexanoate, increased the anti-HIV replication activity compared with 2 by 2-fold while compounds 40, 41, 48, and 49, with C-28 piperazine or piperidine amide substitutions, increased the activity by 3- to 15-fold. The best new compound, 41, exhibited an anti-HIV IC50 of 0.0059 mu M compared with 0.087 mu M antimaturation effects, as confirmed by TZM-bl assay, in blocking the HIV replication. The results suggest that proper C-28 substitutions can further enhance the antimaturation activity of 2 without any antientry effects. Thus, 41 may serve as a promising new lead for development of anti-AIDS clinical trial candidates.